RAP 0.00% 20.5¢ resapp health limited

Game On, page-447

  1. 275 Posts.
    lightbulb Created with Sketch. 55
    Just to recap for those who can't listen at work:

    1250 plus patients enrolled, study is complete and results are being analyzed now
    Mid to late July the results are expected
    Submission to FDA de novo class 2 in August
    FDA clearance expected before end of calendar year

    This part is interesting:
    Pricing model is to charge every time the test is used in consultation, they are looking at around 5 to 10 USD each test. They expect at least "in the 10's of millions" of tests to take place in the states alone.
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.